Harmony Biosciences Holdings Inc
Company Profile
Business description
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Contact
630 W. Germantown Pike
Suite 215
Plymouth MeetingPA19462
USAT: +1 484 539-9800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
268
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,770.20 | 79.30 | 0.91% |
| CAC 40 | 7,804.67 | 40.83 | 0.53% |
| DAX 40 | 24,276.48 | 184.86 | 0.77% |
| Dow JONES (US) | 42,490.36 | 29.28 | -0.07% |
| FTSE 100 | 8,801.29 | 14.27 | 0.16% |
| HKSE | 23,654.03 | 141.54 | 0.60% |
| NASDAQ | 19,413.81 | 14.85 | 0.08% |
| Nikkei 225 | 37,747.45 | 300.64 | 0.80% |
| NZX 50 Index | 12,494.71 | 167.48 | 1.36% |
| S&P 500 | 5,969.69 | 0.68 | -0.01% |
| S&P/ASX 200 | 8,541.80 | 75.10 | 0.89% |
| SSE Composite Index | 3,376.20 | 14.23 | 0.42% |